Conditional approval of a national bank charter used to be a virtual guarantee that an institution would open its doors. But the OCC's recent treatment of Erebor Bank suggests that banks with ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk (NVO) announced on Wednesday that the Supreme People’s Court in China issued a favorable ruling related to the compound patent of semaglutide, the main ingredient in its blockbuster ...

Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine ...

Novo Nordisk (NVO) has launched its recently approved pill version of the blockbuster weight loss treatment, Wegovy, for cash-paying U.S. customers at $149 per month, weeks after its FDA approval in ...

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram and 4 mg doses at $149 per month for self-paying patients in an intensely ...

Americans can now purchase a starter dose of Novo Nordisk’s weight loss drug Wegovy in pill form, the company announced Monday, pledging widespread availability. The 1.5 milligram starter dose of a ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, ...

Novo Nordisk NVO shares have surged 18.8% in the past month. The stock price gain was primarily induced by the much-anticipated FDA approval of NVO’s Wegovy pill (once-daily oral semaglutide 25 mg) ...